



(12) Translation of
European patent specification

(11) NO/EP 3087071 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 471/04 (2006.01)
A61K 31/437 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.01.28
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.09.05
(86)	European Application Nr.	14824743.0
(86)	European Filing Date	2014.12.23
(87)	The European Application's Publication Date	2016.11.02
(30)	Priority	2013.12.24, US, 201361920500 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, USA
(72)	Inventor	NORRIS, Derek J., Bristol-Myers Squibb CompanyRoute 206 & Province Line Road, Princeton, New Jersey 08543, USA DELUCCA, George V., Bristol-Myers Squibb CompanyRoute 206 & Province Line Road, Princeton, New Jersey 08543, USA GAVAI, Ashvinikumar V., Bristol-Myers Squibb CompanyRoute 206 & Province Line Road, Princeton, New Jersey 08543, USA QUESNELLE, Claude A., Bristol-Myers Squibb CompanyRoute 206 & Province Line Road, Princeton, New Jersey 08543, USA GILL, Patrice, Bristol-Myers Squibb CompanyRoute 206 & Province Line Road, Princeton, New Jersey 08543, USA O'MALLEY, Daniel, Bristol-Myers Squibb CompanyRoute 206&Province Line RoadPrinceton, New Jersey 08543, USA VACCARO, Wayne, Bristol-Myers Squibb CompanyRoute 206&Province Line RoadPrinceton, New Jersey 08543, USA LEE, Francis Y., Bristol-Myers Squibb CompanyRoute 206&Province Line RoadPrinceton, New Jersey 08543, USA DEBENEDETTO, Mikkell V., Bristol-Myers Squibb Company5 Research ParkwayWallingford, Connecticut 06492, USA DEGNAN, Andrew P., Bristol-Myers Squibb Company5 Research ParkwayWallingford, Connecticut 06492, USA FANG, Haiquan, 304 County Road, Madison, Connecticut 06443, USA HILL, Matthew D., Bristol-Myers Squibb Company5 Research ParkwayWallingford, Connecticut 06492, USA HUANG, Hong, 475 Powder Hill Road, Durham, Connecticut 06422, USA

SCHMITZ, William D., Bristol-Myers Squibb Company5 Research
ParkwayWallingford, Connecticut 06492, USA
STARRETT, JR, John E., 132 Niantic River Road, Waterford, Connecticut 06385,
USA
HAN, Wen-Ching, Bristol-Myers Squibb Company5 Research ParkwayWallingford,
Connecticut 06492, USA
TOKARSKI, John S., Bristol-Myers Squibb Company5 Research

(74) Agent or Attorney TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge


(54) Title **TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS**

(56) References
Cited: WO-A1-2014/086739, WO-A1-2014/134232, WO-A1-2012/145173, WO-A1-2013/046635,
HEWINGS ET AL.: J. MED. CHEM., vol. 55, 2012, pages 9393-9413, XP055124430, cited in the
application, WO-A1-2014/134267, WO-A1-2014/164596, GÖRLITZER K ET AL: "Reaktionen
von 4,5-Dihydro-4-oxo-1H-pyrido(3,2-b)indol-2- carbonsäure-estern 1-3", DIE PHARMAZIE,
GOVI VERLAG PHARMAZEUTISCHER VERLAG GMBH, ESCHBORN, DE, vol. 55, no. 4, 1
January 2000 (2000-01-01), pages 273-281, XP001526711, ISSN: 0031-7144, CONWAY: ACS
MED. CHEM. LETT., vol. 3, 2012, pages 691-694, XP055124436, cited in the application

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

5




1. Forbindelse med formel (I)

(I)


hvor

A er

10



15



;

20

R er uavhengig av hverandre ett eller flere hydrogen, CD₃, halogen, halogenalkyl, hydroksyalkyl, CN, CF₃, CH₂F, CHF₂, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert (C₁-C₆)alkoksy, eventuelt substituert (C₃-C₆)sykloalkyl, eventuelt substituert heterosyklo, -OR⁴, -CONR³R⁴, -NR³R⁴, NR³R⁴(C₁-C₆)alkyl-, -NR⁶OCOR³, -NR⁶COR³, NR⁶COR³(C₁-C₆)alkyl-, -NR⁶CO₂R³, NR⁶CO₂R³(C₁-C₆)alkyl-, -NR⁶CONR³R⁴, -SO₂NR³R⁴, SO₂(C₁-C₆)alkyl-, -NR⁶SO₂NR³R⁴, -NR⁶SO₂R⁴ eller NR⁶SO₂R⁴(C₁-C₆)alkyl-;

X og Y er uavhengig valgt blant hydrogen, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert (C₃-C₈)sykloalkyl, eventuelt substituert aryl, eventuelt substituert heteroaryl eller eventuelt substituert heterosyklo;

Z er hydrogen, halogen, -OH, (C₁-C₆)alkyl, (C₁-C₆)alkoksy, -NR³R⁴, -CONR³R⁴,

5 -OCONR³R⁴, -NR⁶OCOR³, -NR⁶CONR³R⁴, -NR⁶SO₂NR³R⁴ eller -NR⁶SO₂R⁴;

R¹ er hydrogen, halogen, -CN, -OR⁴, -NR³R⁴, -CONR³R⁴, -COOH, -OCONR³R⁴, -NR⁶OCOR³, -NR⁶CONR³R⁴, -NR⁶SO₂NR³R⁴, -NR⁶SO₂R⁴, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert (C₂-C₆)alkenyl, eventuelt substituert (C₂-C₆)alkynyl, eventuelt substituert (C₁-C₆)alkoksy, eventuelt substituert (C₃-C₈)sykloalkyl, eventuelt substituert

10 (C₃-C₈)sykloalkyl (C₁-C₆)alkyl, eventuelt substituert (C₃-C₈)sykloalkyl-CO-, eventuelt substituert (C₃-C₈)sykloalkyl-SO₂-, eventuelt substituert aryl (C₁-C₆)alkoksy, eventuelt substituert (C₃-C₈)sykloalkyl-(C₁-C₆)alkoksy, eventuelt substituert heterosyklyl-CO-, eventuelt substituert heterosyklyl, eventuelt substituert (C₁-C₆)alkyl-SO₂-, -NR⁶SO₂- eventuelt substituert (C₁-C₆)alkyl, -NR⁶SO₂-eventuelt substituert heterosyklo, eventuelt substituert (C₁-C₆)alkyl-NR⁶SO₂- eller eventuelt substituert heterosyklo-NR⁶SO₂-;

R² er hydrogen, halogen, -CN, OH, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert (C₃-C₈)sykloalkyl, eventuelt substituert (C₁-C₆)alkoksy, eventuelt substituert aryl, eventuelt substituert heteroaryl eller eventuelt substituert heterosyklo;

R³ er hydrogen, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert

20 (C₃-C₈)sykloalkyl, eventuelt substituert (C₂-C₆)alkenyl, eventuelt substituert (C₂-C₆)alkynyl, cyano(C₁-C₆)alkyl, hydroksy(C₁-C₆)alkyl, eventuelt substituert aryl, eventuelt substituert aryl(C₁-C₆)alkyl, eventuelt substituert aryloksy(C₁-C₆)alkyl, eventuelt substituert (C₁-C₆)alkyl-SO₂-, eventuelt substituert heterosyklyl, eventuelt substituert heterosyklyl(C₁-C₆)alkyl, eventuelt substituert heteroaryl eller eventuelt substituert heteroaryl(C₁-C₆)alkyl,

25 R⁴ er hydrogen, eventuelt substituert (C₁-C₆)alkyl eller eventuelt substituert (C₃-C₈)sykloalkyl;

eller R³ og R⁴ kan tas sammen med nitrogenatomet som de er bundet til for å danne en eventuelt substituert (C₄-C₈)heteroaryl- eller (C₄-C₈)-heterosyklisk ring;

30 R⁶ er hydrogen eller eventuelt substituert (C₁-C₆)alkyl;

og/eller et farmasøytisk akseptabelt salt, tautomer eller stereoisomer derav;


hvor begrepet aryl, enten alene eller som del av en større del, refererer til monosykliske, bisykliske og trisykliske ringsystemer som har totalt 5 til 15 ringmedlemmer, hvor minst en ring i systemet er aromatisk og hvor hver ring i systemet inneholder tre til syv

35 ringmedlemmer;

og hvor begrepet heterosyklo eller heterosyklisk refererer til en stabil 3-, 4-, 5-, 6- eller 7-leddet monosyklisk eller bisyklisk eller 7-, 8-, 9-, 10-, 11-, 12-, 13- eller 14-leddet polysyklisk heterosyklisk ring som er mettet, delvis umettet eller fullstendig umettet, og


som inneholder karbonatomer og 1, 2, 3 eller 4 heteroatomer uavhengig valgt blant gruppen som består av N, O og S; og inkluderer enhver polysyklisk gruppe der noen av de ovenfor definerte heterosykliske ringene er fusjonert til en benzenring.

5 **2.** Forbindelse ifølge krav 1 med formelen



hvor:

A er



15 ;

R er uavhengig av hverandre ett eller flere hydrogen, CD₃, halogen, halogenalkyl, hydroksyalkyl, CN, CF₃, CH₂F, CHF₂, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert (C₁-C₆)alkoksy, eventuelt substituert (C₃-C₆)sykloalkyl, eventuelt substituert heterosyklo, -OR⁴, -CONR³R⁴, -NR³R⁴, NR³R⁴(C₁-C₆)alkyl-, -NR⁶OCOR³, -NR⁶COR³, NR⁶COR³(C₁-C₆)alkyl-, -NR⁶CO₂R³, NR⁶CO₂R³(C₁-C₆)alkyl-, -NR⁶CONR³R⁴, -SO₂NR³R⁴, SO₂(C₁-C₆)alkyl-, -NR⁶SO₂NR³R⁴, -NR⁶SO₂R⁴ eller NR⁶SO₂R⁴(C₁-C₆)alkyl-;

20

X og Y er uavhengig valgt blant hydrogen, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert (C₃-C₈)sykloalkyl, eventuelt substituert aryl, eventuelt substituert heteroaryl eller eventuelt substituert heterosyklo;

Z er hydrogen, halogen, -OH, (C₁-C₆)alkyl, (C₁-C₆)alkoksy, -NR³R⁴, -CONR³R⁴,

5 -OCONR³R⁴, -NR⁶OCOR³, -NR⁶CONR³R⁴, -NR⁶SO₂NR³R⁴ eller -NR⁶SO₂R⁴;

R¹ er hydrogen, halogen, -CN, -OR⁴, -NR³R⁴, -CONR³R⁴, -COOH, -OCONR³R⁴, -NR⁶OCOR³, -NR⁶CONR³R⁴, -NR⁶SO₂NR³R⁴, -NR⁶SO₂R⁴, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert (C₂-C₆)alkenyl, eventuelt substituert (C₂-C₆)alkynyl, eventuelt substituert (C₁-C₆)alkoksy, eventuelt substituert (C₃-C₈)sykloalkyl, eventuelt substituert

10 (C₃-C₈)sykloalkyl-(C₁-C₆)alkyl, eventuelt substituert (C₃-C₈)sykloalkyl-CO-, eventuelt substituert (C₃-C₈)sykloalkyl-SO₂-, eventuelt substituert aryl-(C₁-C₆)alkoksy, eventuelt substituert (C₃-C₈)sykloalkyl-(C₁-C₆)alkoksy, eventuelt substituert heterosyklyl-CO-, eventuelt substituert heterosyklyl, eventuelt substituert (C₁-C₆)alkyl-SO₂-, -NR⁶SO₂- eventuelt substituert (C₁-C₆)alkyl, -NR⁶SO₂-eventuelt substituert heterosyklo, eventuelt substituert (C₁-C₆)alkyl-NR⁶SO₂- eller eventuelt substituert heterosyklo-NR⁶SO₂-;

R² er hydrogen, halogen, -CN, OH, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert (C₃-C₈)sykloalkyl, eventuelt substituert (C₁-C₆)alkoksy, eventuelt substituert aryl, eventuelt substituert heteroaryl eller eventuelt substituert heterosyklo;

R³ er hydrogen, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert

20 (C₃-C₈)sykloalkyl, eventuelt substituert (C₂-C₆)alkenyl, eventuelt substituert (C₂-C₆)alkynyl, cyano(C₁-C₆)alkyl, hydroksy(C₁-C₆)alkyl, eventuelt substituert aryl, eventuelt substituert aryl(C₁-C₆)alkyl, eventuelt substituert aryloksy(C₁-C₆)alkyl, eventuelt substituert (C₁-C₆)alkyl-SO₂-, eventuelt substituert heterosyklyl, eventuelt substituert heterosyklyl(C₁-C₆)alkyl, eventuelt substituert heteroaryl eller eventuelt substituert heteroaryl(C₁-C₆)alkyl,


25 R⁴ er hydrogen, eventuelt substituert (C₁-C₆)alkyl eller eventuelt substituert (C₃-C₈)sykloalkyl;

eller R³ og R⁴ kan tas sammen med nitrogenatomet som de er bundet til for å danne en eventuelt substituert (C₄-C₈)heteroaryl- eller (C₄-C₈)-heterosyklisk ring;

30 R⁶ er hydrogen eller eventuelt substituert (C₁-C₆)alkyl;


og/eller et farmasøytisk akseptabelt salt, tautomer eller stereoisomer derav.

3. Forbindelse ifølge krav 1 eller 2 med formelen



hvor:

A er



5

R er uavhengig av hverandre ett eller flere hydrogen, CD₃, halogen, halogenalkyl, hydroksyalkyl, CN, CF₃, CH₂F, CHF₂, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert (C₁-C₆)alkoksy, eventuelt substituert (C₃-C₆)sykloalkyl, eventuelt substituert heterosyklo, -OR⁴, -CONR³R⁴, -NR³R⁴, NR³R⁴(C₁-C₆)alkyl-, -NR⁶OCOR³, -NR⁶COR³, NR⁶COR³(C₁-C₆)alkyl-, -NR⁶CO₂R³, NR⁶CO₂R³(C₁-C₆)alkyl-, -NR⁶CONR³R⁴, -SO₂NR³R⁴, SO₂(C₁-C₆)alkyl-, -NR⁶SO₂NR³R⁴, -NR⁶SO₂R⁴ eller NR⁶SO₂R⁴(C₁-C₆)alkyl-;

10

X og Y er uavhengig valgt blant hydrogen, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert (C₃-C₈)sykloalkyl, eventuelt substituert aryl, eventuelt substituert heteroaryl eller eventuelt substituert heterosyklo;

15

Z er hydrogen, halogen, -OH, (C₁-C₆)alkyl, (C₁-C₆)alkoksy, -NR³R⁴, -CONR³R⁴, -OCONR³R⁴, -NR⁶OCOR³, -NR⁶CONR³R⁴, -NR⁶SO₂NR³R⁴ eller -NR⁶SO₂R⁴;

R¹ er hydrogen, halogen, -CN, -OR⁴, -NR³R⁴, -CONR³R⁴, -COOH, -OCONR³R⁴, -NR⁶OCOR³, -NR⁶CONR³R⁴, -NR⁶SO₂NR³R⁴, -NR⁶SO₂R⁴, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert (C₂-C₆)alkenyl, eventuelt substituert (C₂-C₆)alkynyl, eventuelt substituert (C₁-C₆)alkoksy, eventuelt substituert (C₃-C₈)sykloalkyl, eventuelt substituert (C₃-C₈)sykloalkyl-(C₁-C₆)alkyl, eventuelt substituert (C₃-C₈)sykloalkyl-CO-, eventuelt substituert (C₃-C₈)sykloalkyl-SO₂-, eventuelt substituert aryl-(C₁-C₆)alkoksy, eventuelt substituert (C₃-C₈)sykloalkyl-(C₁-C₆)alkoksy, eventuelt substituert heterosyklyl-CO-, eventuelt substituert heterosyklyl, eventuelt substituert (C₁-C₆)alkyl-SO₂-, -NR⁶SO₂- eventuelt substituert (C₁-C₆)alkyl, -NR⁶SO₂-eventuelt substituert heterosyklo, eventuelt substituert (C₁-C₆)alkyl-NR⁶SO₂- eller eventuelt substituert heterosyklo-NR⁶SO₂-;

R² er hydrogen, halogen, -CN, OH, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert (C₃-C₈)sykloalkyl, eventuelt substituert (C₁-C₆)alkoksy, eventuelt substituert aryl, eventuelt substituert heteroaryl eller eventuelt substituert heterosyklo;

25

R^3 er hydrogen, eventuelt substituert (C_1 - C_6)alkyl, eventuelt substituert (C_3 - C_8)sykloalkyl, eventuelt substituert (C_2 - C_6)alkenyl, eventuelt substituert (C_2 - C_6)alkynyl, cyano(C_1 - C_6)alkyl, hydroksy(C_1 - C_6)alkyl, eventuelt substituert aryl, eventuelt substituert aryl(C_1 - C_6)alkyl, eventuelt substituert aryloksy(C_1 - C_6)alkyl, eventuelt substituert (C_1 - C_6)alkyl-SO₂-, eventuelt substituert heterosyklyl, eventuelt substituert heterosyklyl(C_1 - C_6)alkyl, eventuelt substituert heteroaryl eller eventuelt substituert heteroaryl(C_1 - C_6)alkyl,


R^4 er hydrogen, eventuelt substituert (C_1 - C_6)alkyl eller eventuelt substituert (C_3 - C_8)sykloalkyl;

eller R^3 og R^4 kan tas sammen med nitrogenatomet som de er bundet til for å danne en eventuelt substituert (C_4 - C_8)heteroaryl- eller (C_4 - C_8)-heterosyklisk ring;

R^6 er hydrogen eller eventuelt substituert (C_1 - C_6)alkyl;


og/eller et farmasøytisk akseptabelt salt, tautomer eller stereoisomer derav.

4. Forbindelse ifølge et hvilket som helst av krav 1 til 3 med formelen



hvor:

A er



X og Y er uavhengig valgt blant hydrogen, eventuelt substituert (C_1 - C_6)alkyl, eventuelt substituert (C_3 - C_8)sykloalkyl, eventuelt substituert aryl, eventuelt substituert heteroaryl eller eventuelt substituert heterosyklo;

Z er hydrogen, halogen, -OH, (C_1 - C_6)alkyl, (C_1 - C_6)alkoksy, -NR³R⁴, -CONR³R⁴, -OCONR³R⁴, -NR⁶OCOR³, -NR⁶CONR³R⁴, -NR⁶SO₂NR³R⁴ eller -NR⁶SO₂R⁴;

- R¹ er hydrogen, halogen, -CN, -OR⁴, -NR³R⁴, -CONR³R⁴, -COOH, -OCONR³R⁴, -NR⁶OCOR³, -NR⁶CONR³R⁴, -NR⁶SO₂NR³R⁴, -NR⁶SO₂R⁴, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert (C₂-C₆)alkenyl, eventuelt substituert (C₂-C₆)alkynyl, eventuelt substituert (C₁-C₆)alkoksy, eventuelt substituert (C₃-C₈)sykloalkyl, eventuelt substituert
- 5 (C₃-C₈)sykloalkyl-(C₁-C₆)alkyl, eventuelt substituert (C₃-C₈)sykloalkyl-CO-, eventuelt substituert (C₃-C₈)sykloalkyl-SO₂-, eventuelt substituert aryl-(C₁-C₆)alkoksy, eventuelt substituert (C₃-C₈)sykloalkyl-(C₁-C₆)alkoksy, eventuelt substituert heterosyklyl-CO-, eventuelt substituert heterosyklyl, eventuelt substituert (C₁-C₆)alkyl-SO₂-, -NR⁶SO₂- eventuelt substituert (C₁-C₆)alkyl, -NR⁶SO₂-eventuelt substituert heterosyklo, eventuelt
- 10 substituert (C₁-C₆)alkyl-NR⁶SO₂- eller eventuelt substituert heterosyklo-NR⁶SO₂-; R² er hydrogen, halogen, -CN, OH, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert (C₃-C₈)sykloalkyl, eventuelt substituert (C₁-C₆)alkoksy, eventuelt substituert aryl, eventuelt substituert heteroaryl eller eventuelt substituert heterosyklo;
- R³ er hydrogen, eventuelt substituert (C₁-C₆)alkyl, eventuelt substituert
- 15 (C₃-C₈)sykloalkyl, eventuelt substituert (C₂-C₆)alkenyl, eventuelt substituert (C₂-C₆)alkynyl, cyano(C₁-C₆)alkyl, hydroksy(C₁-C₆)alkyl, eventuelt substituert aryl, eventuelt substituert aryl(C₁-C₆)alkyl, eventuelt substituert aryloksy(C₁-C₆)alkyl, eventuelt substituert (C₁-C₆)alkyl-SO₂-, eventuelt substituert heterosyklyl, eventuelt substituert heterosyklyl(C₁-C₆)alkyl, eventuelt substituert heteroaryl eller eventuelt
- 20 substituert heteroaryl(C₁-C₆)alkyl, R⁴ er hydrogen, eventuelt substituert (C₁-C₆)alkyl eller eventuelt substituert (C₃-C₈)sykloalkyl;
- eller R³ og R⁴ kan tas sammen med nitrogenatomet som de er bundet til for å danne en eventuelt substituert (C₄-C₈)heteroaryl- eller (C₄-C₈)-heterosyklisk ring;
- 25 R⁶ er hydrogen eller eventuelt substituert (C₁-C₆)alkyl; og/eller et farmasøytisk akseptabelt salt, tautomer eller stereoisomer derav.

5. Forbindelse ifølge krav 1, valgt blant de følgende:

- 2-[3-(dimetyl-1H-1,2,3-triazol-5-yl)-5-(1,1,1,7,7,7-heksafluorheptan-4-yl)-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol,
- 30 2-[3-(dimetyl-1,2-oksazol-4-yl)-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol,
- 2-[3-(dimetyl-1H-1,2,3-triazol-5-yl)-5-[(1S)-4,4,4-trifluor-1-fenylbutyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol,
- 35 2-[3-(dimetyl-1H-1,2,3-triazol-5-yl)-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol,
- 2-[3-(dimetyl-1,2-oksazol-4-yl)-5-[(S)-(4-fluorfenyl)(oksan-4-yl)metyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol,

- 2-[3-(dimetyl-1H-1,2,3-triazol-5-yl)-5-[(4-fluorfenyl)(oksan-4-yl)metyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol,
- 2-[3-(dimetyl-1H-1,2,3-triazol-5-yl)-6-fluor-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol,
- 5 2-{3-[4-(hydroksymetyl)-1-metyl-1H-1,2,3-triazol-5-yl]-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
- 5-{7-metansulfonyl-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-3-yl}-4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol,
- 5-{5-[(S)-(4-fluorfenyl)(oksan-4-yl)metyl]-7-metansulfonyl-5H-pyrido[3,2-b]indol-3-yl}-4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol,
- 10 2-{5-[(S)-(4-fluorfenyl)(oksan-4-yl)metyl]-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
- (1R)-1-syklopropyl-1-[3-(dimetyl-1H-1,2,3-triazol-5-yl)-6-fluor-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl]etan-1-ol,
- 15 2-{3-[5-(²H₃)metyl-3-metyl-1,2-oksazol-4-yl]-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol
- 2-{3-[4-(²H₃)metoksy-1-metyl-1H-1,2,3-triazol-5-yl]-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
- 2-[3-(4-metoksy-1-metyl-1H-1,2,3-triazol-5-yl)-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol,
- 20 (1R)-1-syklopropyl-1-[3-(dimetyl-1H-1,2,3-triazol-5-yl)-6-fluor-5-[(S)-(2-fluorfenyl)(oksan-4-yl)metyl]-5H-pyrido[3,2-b]indol-7-yl]etan-1-ol,
- 2-{6-fluor-5-[(S)-(2-fluorfenyl)(oksan-4-yl)metyl]-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
- 25 (1S)-1-syklopropyl-1-{6-fluor-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl}etan-1-ol,
- (1R)-1-syklopropyl-1-{6-fluor-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl}etan-1-ol,
- 2-{5-[(3-fluorpyridin-2-yl)(oksan-4-yl)metyl]-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
- 30 2-{8-fluor-5-[(S)-(2-fluorfenyl)(oksan-4-yl)metyl]-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
- 2-{6-fluor-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
- 35 2-{5-[(S)-(4,4-difluorsykloheksyl)(fenyl)metyl]-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
- 2-{8-fluor-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,

- (1R)-1-syklopropyl-1-{6-fluor-5-[(S)-(2-fluorfenyl)(oksan-4-yl)metyl]-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-7-yl}etan-1-ol,
 2-{6-fluor-5-[(5-metyl-1,2-oksazol-3-yl)(oksan-4-yl)metyl]-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
 5 2-{6-klor-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
 2-[(R)-(4,4-difluorsykloheksyl){9-fluor-7-metansulfonyl-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-5-yl})metyl]-3-fluorpyridin,
 (1S)-1-syklopropyl-1-{6-fluor-5-[(S)-(2-fluorfenyl)(oksan-4-yl)metyl]-3-[4-(²H₃)metyl-1-
 10 metyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-7-yl}etan-1-ol,
 2-{8-fluor-5-[(5-metyl-1,2-oksazol-3-yl)(oksan-4-yl)metyl]-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
 2-{5-[(5-klorpyridin-2-yl)(oksan-4-yl)metyl]-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
 15 2-{5-[(3-klorpyridin-2-yl)(oksan-4-yl)metyl]-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
 2-{5-[(4-klorpyridin-2-yl)(oksan-4-yl)metyl]-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
 2-{5-[(4,4-difluorsykloheksyl)(3-fluorpyridin-2-yl)metyl]-6-fluor-3-[4-(²H₃)metyl-1-
 20 metyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
 2-{6-fluor-5-[(3-fluorpyridin-2-yl)(oksan-4-yl)metyl]-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
 2-{8-fluor-5-[(3-fluorpyridin-2-yl)(oksan-4-yl)metyl]-3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
 25 2-{3-[4-(²H₃)metoksy-1-(²H₃)metyl-1H-1,2,3-triazol-5-yl]-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
 2-{3-[4-metoksy-1-(²H₃)metyl-1H-1,2,3-triazol-5-yl]-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,
 5-{7-metansulfonyl-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-3-yl}-4-
 30 metoksy-1-metyl-1H-1,2,3-triazol,
 2-[3-(dimetyl-1H-1,2,3-triazol-5-yl)-6-fluor-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-amin,
 N-{2-[3-(dimetyl-1H-1,2,3-triazol-5-yl)-6-fluor-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-yl}acetamid,
 35 N-{2-[3-(dimetyl-1H-1,2,3-triazol-5-yl)-6-fluor-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-yl}metansulfonamid,
 metyl-N-{2-[3-(dimetyl-1H-1,2,3-triazol-5-yl)-6-fluor-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-yl}karbamat,

5-{6-metansulfonyl-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-3-yl}-1,4-dimetyl-1H-1,2,3-triazol,

5-{9-fluor-6-metansulfonyl-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-3-yl}-4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol,

5 5-{6-metansulfonyl-9-metoksy-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-3-yl}-1,4-dimetyl-1H-1,2,3-triazol,

N-[3-(dimetyl-1H-1,2,3-triazol-5-yl)-6-metansulfonyl-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-9-yl]syklopropansulfonamid,

10 5-{9-metansulfonyl-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-3-yl}-1,4-dimetyl-1H-1,2,3-triazol,

5-{9-fluor-7-metansulfonyl-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-3-yl}-4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol, or

2-{3-[4-(²H₃)metyl-1-metyl-1H-1,2,3-triazol-5-yl]-5-[(S)-oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol,


15 og/eller et farmasøytisk akseptabelt salt, tautomer eller stereoisomer derav.

6. Forbindelse ifølge krav 1, som er (S)-2-[3-(dimetyl-1H-1,2,3-triazol-5-yl)-5-[oksan-4-yl(fenyl)metyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol,


og/eller et farmasøytisk akseptabelt salt, tautomer eller stereoisomer derav.

20

7. Forbindelse, valgt blant de følgende:



25



- 8.** Farmasøytisk sammensetning som omfatter en forbindelse ifølge et hvilket som helst av kravene 1 til 7 og en eller flere farmasøytisk akseptable bærere, fortynningsmidler eller eksipienser.
- 9.** Farmasøytisk kombinasjonsprodukt som omfatter en forbindelse ifølge et hvilket som helst av kravene 1 til 7 sammen med ett eller flere andre terapeutisk aktive midler.
- 10. 10.** Forbindelse ifølge et hvilket som helst av krav 1 til 7 for anvendelse i behandling.
- 11.** Forbindelse ifølge et hvilket som helst av krav 1 til 7 for anvendelse i behandling av sykdommer eller tilstander som en bromdomeneinhibitor er indikert for.
- 12.** Forbindelsen for anvendelsen ifølge krav 11, hvori sykdommen eller tilstanden er kreft.
- 13.** Forbindelse ifølge et hvilket som helst av krav 1 til 7 for anvendelse i en fremgangsmåte for behandling av kreft.
- 14.** Forbindelsen for anvendelsen ifølge krav 13, hvori kreften er småcellet lungekreft, ikke-småcellet lungekreft, kolorektal kreft, multippelt myelom, akutt myeloid leukemi (AML), akutt lymfoblastisk leukemi (ALL), bukspyttkjertelkreft, leverkreft, hepatocellulær kreft, nevroblastom, andre faste tumorer eller andre hematologiske kreftformer.
- 15.** Forbindelsen for anvendelsen ifølge krav 13, hvori kreften er småcellet lungekreft, ikke-småcellet lungekreft, kolorektal kreft, multippelt myelom eller AML.